A previous meta-analysis comprising of 41 clinical trials of PD-1/PD-L1 inhibitors with available PD-L1 biomarker data showed that tumor and tumor-infiltrating immune cell with PD-L1 overexpression was significantly associated with higher response rates to immune checkpoint inhibitors across a range of solid tumors. The gene discussed is CD274; the disease is neoplasm.